What targeted therapy options are recommended for a patient with metastatic non‑liposarcoma soft‑tissue sarcoma who has progressed after at least one line of anthracycline‑based chemotherapy?

Targeted Therapy for Metastatic Non-Liposarcoma Soft Tissue Sarcoma After Anthracycline Failure

Pazopanib is the primary targeted therapy option for metastatic non-liposarcoma soft tissue sarcoma after anthracycline failure, providing a 3-month progression-free survival benefit with Level I evidence. 1, 2

First-Line Targeted Therapy Options

For patients who have progressed after anthracycline-based chemotherapy, the treatment algorithm should proceed as follows:

Primary Recommendation: Pazopanib

• Pazopanib is specifically indicated for non-adipogenic (non-liposarcoma) STS with Level I, Grade B evidence 1, 2
• Provides median PFS benefit of approximately 3 months compared to placebo
• Approved and commercially available in most regions
• Critical caveat: Explicitly excludes liposarcomas from its indication

Alternative Targeted Therapy: Regorafenib

• Regorafenib is a second-choice targeted agent for non-adipogenic STS after doxorubicin failure 2
• Demonstrated PFS improvement in randomized placebo-controlled phase II trial
• Level II, Grade C evidence
• Important limitation: No survival advantage observed in liposarcoma cohort, making it appropriate only for non-liposarcoma subtypes

Histology-Specific Targeted Approaches

The guidelines emphasize that certain rare subtypes have specific targeted therapies with stronger evidence:

NTRK Fusion-Positive Sarcomas

• Larotrectinib or entrectinib are standard first-line treatments for NTRK-rearranged sarcomas 3
• Level III, Grade A evidence with ESMO-MCBS score of 3
• Requires molecular confirmation after positive pan-NTRK immunohistochemistry (sensitivity ~80%, specificity ~75% in STS)

Rare Molecular Subtypes

• mTOR inhibitors for malignant PEComas (associated with TSC1/TSC2 loss) 1, 2
• Crizotinib for inflammatory myofibroblastic tumors with ALK translocations 1, 2
• Sunitinib for alveolar soft part sarcoma and solitary fibrous tumors 1, 2, 4
• All carry Level IV, Grade C evidence but represent important options for these specific entities

Non-Targeted Second-Line Options

While not strictly "targeted therapy," these agents warrant mention as they may be considered alongside or before targeted agents:

Trabectedin

• Approved for second-line and beyond treatment 2, 3
• Level I, Grade B evidence
• Particularly effective in leiomyosarcoma and liposarcoma, but shows clinical benefit across other histological types
• Not specifically a "targeted" therapy but has preferential activity in certain subtypes

Ifosfamide

• High-dose ifosfamide (14 g/m²) if not previously received or if only standard-dose (9 g/m²) was given 1, 2
• Level IV, Grade C evidence

Critical Decision Points

The key algorithmic decision is histology-based:

1. First, confirm histology: Is this truly non-liposarcoma STS?

   • If liposarcoma → pazopanib is NOT indicated
   • If non-liposarcoma → proceed to step 2

2. Second, check for actionable mutations:

   • NTRK fusion → larotrectinib/entrectinib (highest priority)
   • ALK translocation (inflammatory myofibroblastic tumor) → crizotinib
   • TSC1/TSC2 loss (PEComa) → mTOR inhibitors

3. Third, if no actionable mutations in non-liposarcoma STS:

   • Pazopanib is the primary targeted therapy choice 2
   • Regorafenib as alternative if pazopanib unavailable or after pazopanib failure

4. Consider non-targeted options (trabectedin, ifosfamide, gemcitabine/dacarbazine combinations) based on prior treatments and performance status

Common Pitfalls to Avoid

• Do not use pazopanib in liposarcomas - it was specifically excluded from the pivotal trial and has no demonstrated benefit 1, 2
• Do not assume all "targeted therapies" work across all STS subtypes - the heterogeneity of STS demands histology-specific approaches
• Do not overlook molecular testing - NTRK fusions, though rare, have highly effective targeted treatments that should not be missed
• Do not forget that pazopanib's 3-month PFS benefit, while statistically significant, is modest and must be weighed against toxicity (cardiovascular, gastrointestinal, hepatic disorders, palmoplantar erythrodysaesthesia) 5

Strength of Evidence Assessment

The most recent and highest-quality evidence comes from the 2018 and 2021 ESMO-EURACAN guidelines 2, 3, which consistently recommend pazopanib as Level I, Grade B evidence for non-adipogenic STS. This represents the strongest recommendation for a true "targeted therapy" in this population, though the clinical benefit remains modest compared to targeted therapies in other malignancies.